Clinical trial reportCancer immunology, immunotherapy : CIIPublished
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- Counties
- Chester County, Mercer County, Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Cancer immunology, immunotherapy : CII
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Neoplasms; Injections, Subcutaneous; Adult; Aged; Middle Aged; Female; Male; Antibodies, Monoclonal, Humanized; Programmed Cell Death 1 Receptor; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors
- PubMed ID
- 42313189
- PubMed Central ID
- PMC13522328
- Open access
- Yes, open
- Added to directory
- Source checked